Holen Sie sich die Stockscreener-App
12.74
2.08%
-0.27
Handel nachbörslich:
12.74
Schlusskurs vom Vortag:
$13.01
Offen:
$12.98
24-Stunden-Volumen:
1.04M
Relative Volume:
0.54
Marktkapitalisierung:
$1.63B
Einnahmen:
-
Nettoeinkommen (Verlust:
$-29.07M
KGV:
-43.93
EPS:
-0.29
Netto-Cashflow:
$-31.85M
1W Leistung:
+1.03%
1M Leistung:
+15.92%
6M Leistung:
+113.76%
1J Leistung:
+214.57%
1-Tages-Spanne:
$12.68
$13.16
1-Wochen-Bereich:
$11.91
$13.22
52-Wochen-Spanne:
$3.4715
$14.39
Trevi Therapeutics Inc Stock (TRVI) Company Profile
Firmenname
Trevi Therapeutics Inc
Sektor
Branche
Telefon
203-304-2499
Adresse
195 CHURCH STREET, NEW HAVEN, CT
Vergleichen Sie TRVI mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
TRVI
Trevi Therapeutics Inc
|
12.74 | 1.67B | 0 | -29.07M | -31.85M | -0.29 |
|
VRTX
Vertex Pharmaceuticals Inc
|
460.31 | 115.75B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
779.36 | 80.71B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
407.73 | 52.88B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
852.04 | 52.64B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
175.76 | 37.29B | 447.02M | -1.18B | -906.14M | -6.1812 |
Trevi Therapeutics Inc Stock (TRVI) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-11-13 | Eingeleitet | Leerink Partners | Outperform |
| 2025-08-21 | Eingeleitet | Morgan Stanley | Overweight |
| 2025-07-01 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2025-05-28 | Eingeleitet | H.C. Wainwright | Buy |
| 2025-03-10 | Bestätigt | Needham | Buy |
| 2025-03-10 | Hochstufung | Raymond James | Outperform → Strong Buy |
| 2024-12-12 | Bestätigt | H.C. Wainwright | Buy |
| 2024-09-09 | Fortgesetzt | Leerink Partners | Outperform |
| 2024-08-30 | Eingeleitet | H.C. Wainwright | Buy |
| 2024-08-30 | Eingeleitet | Raymond James | Outperform |
| 2024-06-13 | Eingeleitet | Rodman & Renshaw | Buy |
| 2023-04-12 | Eingeleitet | B. Riley Securities | Buy |
| 2022-11-22 | Eingeleitet | SVB Leerink | Outperform |
| 2019-06-03 | Eingeleitet | BMO Capital Markets | Outperform |
| 2019-06-03 | Eingeleitet | Needham | Buy |
| 2019-06-03 | Eingeleitet | SVB Leerink | Outperform |
| 2019-06-03 | Eingeleitet | Stifel | Buy |
Alle ansehen
Trevi Therapeutics Inc Aktie (TRVI) Neueste Nachrichten
Trevi Therapeutics (TRVI) Targets Next Phase of Growth with Leadership Change - Finviz
Flputnam Investment Management Co. Raises Stock Holdings in Trevi Therapeutics, Inc. $TRVI - MarketBeat
Is Trevi Therapeutics Inc. stock cheap at current valuationJuly 2025 PreEarnings & High Yield Equity Trading Tips - Улправда
Will Trevi Therapeutics Inc. stock rally after Fed decisionsRisk Management & Low Risk Growth Stock Ideas - Улправда
Stifel Maintains Trevi Therapeutics (TRVI) Buy Recommendation - Nasdaq
Wall Street Analysts Predict a 231.05% Upside in Trevi Therapeutics (TRVI): Here's What You Should Know - MSN
Trevi Therapeutics stock price target raised to $18 by Stifel on cough drug potential - Investing.com Canada
TRVI: Stifel Raises Price Target and Maintains Buy Rating | TRVI Stock News - GuruFocus
What dividend safety score for Trevi Therapeutics Inc. stockJuly 2025 Analyst Calls & Weekly Top Gainers Trade List - DonanımHaber
Why Trevi Therapeutics Inc. stock remains on buy listsJuly 2025 Chart Watch & Comprehensive Market Scan Reports - DonanımHaber
Can Trevi Therapeutics Inc. stock sustain market leadershipWeekly Profit Recap & Free Community Supported Trade Ideas - ulpravda.ru
Trevi Therapeutics, Inc. (NASDAQ:TRVI) Receives Consensus Rating of "Buy" from Analysts - MarketBeat
Trevi Therapeutics stock hits all-time high of 14.01 USD By Investing.com - Investing.com Nigeria
Marshall Wace LLP Has $13.55 Million Stock Position in Trevi Therapeutics, Inc. $TRVI - MarketBeat
Trevi Therapeutics Stock Surges to Record High on Clinical and Strategic Momentum - AD HOC NEWS
Trevi Therapeutics (NASDAQ:TRVI) Hits New 12-Month HighTime to Buy? - MarketBeat
Trevi Therapeutics (NASDAQ:TRVI) Trading 5.7% HigherTime to Buy? - MarketBeat
Trevi Therapeutics stock hits all-time high of 14.01 USD - Investing.com
Trevi Therapeutics, Inc. $TRVI Shares Acquired by Vivo Capital LLC - MarketBeat
226,381 Shares in Trevi Therapeutics, Inc. $TRVI Bought by Prudential Financial Inc. - MarketBeat
Trevi Therapeutics appoints new CFO - MSN
Trevi Therapeutics Appoints New Chief Financial Officer - The Globe and Mail
Affinity Asset Advisors LLC Raises Holdings in Trevi Therapeutics, Inc. $TRVI - MarketBeat
Trevi Therapeutics appoints David Hastings as chief financial officer By Investing.com - Investing.com Nigeria
Trevi Therapeutics, Inc. Announces Appointment of David Hastings as Chief Financial Officer, Effective January 6, 2026 - marketscreener.com
Trevi Therapeutics, Inc. Announces the Hiring of David Hastings to Serve as the Company?s Principal Financial Officer, Effective January 6, 2026 - marketscreener.com
New Haven biotech names new CFO - Hartford Business Journal
Trevi Therapeutics appoints David Hastings as chief financial officer - Investing.com
Trevi Therapeutics, Inc. $TRVI Shares Purchased by Geode Capital Management LLC - MarketBeat
Trevi Therapeutics appoints David Hastings as new CFO By Investing.com - Investing.com Nigeria
Trevi Therapeutics Taps David Hastings as CFO - Contract Pharma
Trevi Therapeutics appoints David Hastings as new CFO - Investing.com India
Trevi Therapeutics, Inc. $TRVI Shares Purchased by Panagora Asset Management Inc. - MarketBeat
Trevi Therapeutics Names David Hastings CFO - marketscreener.com
Trevi Therapeutics announces appointment of David Hastings as chief financial officer - marketscreener.com
Trevi Therapeutics Announces Appointment Of David Hastings As Chief Financial Officer - TradingView — Track All Markets
Trevi Therapeutics Announces Appointment of David Hastings as Chief Financial Officer - cnhinews.com
Trevi Therapeutics edges higher amid takeover speculation - MSN
Trevi Therapeutics: "Buy" Rating For Haduvio Treating Chronic Cough In IPF And Beyond - Seeking Alpha
Trevi Therapeutics stock hits all-time high at 13.92 USD By Investing.com - Investing.com Canada
Trevi Therapeutics stock hits all-time high at 13.92 USD - Investing.com
Trevi Therapeutics (TRVI) Rises on Takeover Speculation - GuruFocus
Trevi Therapeutics edges higher amid takeover speculation (TRVI:NASDAQ) - Seeking Alpha
Trevi Therapeutics (TRVI) Stock Analysis Report | Financials & Insights - Benzinga
Jefferies Financial Group Inc. Makes New Investment in Trevi Therapeutics, Inc. $TRVI - MarketBeat
Trevi Therapeutics Inc Strengthens Strategy For Clinical Design - Kalkine Media
Tejara Capital Ltd Purchases 146,879 Shares of Trevi Therapeutics, Inc. $TRVI - MarketBeat
Finanzdaten der Trevi Therapeutics Inc-Aktie (TRVI)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.67%
1.93%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):